Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun (2020) 24;11(1):4841. PMID: 32973176
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer (2020) 122, 1760-1768. PMID: 32350413
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut (2019) 68(6):1052-1064. PMID: 30121627
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAMindependent manner. Nat Commun (2018) 9(1):3279. PMID: 30115931
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol (2018) 19(4):562-578. PMID: 29611518
Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.